
    
      The randomized portion of the study is a prospective, multicenter, multinational, 2:1
      randomized, single-blinded controlled clinical trial comparing the IPSS of the treatment
      group to the IPSS of the control group at the 3 month follow-up. Subjects in the active
      treatment group undergo UroLift system treatment. Subjects in the control group undergo a
      cystoscopy procedure.

      All subjects will be followed through 12 months, and through 5 years for those that receive
      the investigational device.
    
  